National Psoriasis Foundation Review Examines GLP-1 Receptor Agonists for Psoriasis with Metabolic Comorbidities
This review from the US National Psoriasis Foundation Medical Board provides an evidence-informed narrative synthesis and practical considerations to introduce dermatologists to glucagon-like…
Read the full articleYou might also wanna read
GLP-1 Receptor Agonists Associated With Lower Cardiovascular and Inflammatory Risks in Hidradenitis Suppurativa
As reported on MedPage Today, large retrospective study suggests that glucagon-like peptide-1 (GLP-1) receptor agonists may offer broad heal
Expert panel addresses GLP-1 RAs’ factors, features, and future
Amid increasing attention for GLP-1 RAs, a panel of experts summarized a broad spectrum of topics related to these medications, including em
GLP-1 Receptor Agonists Linked to Small Risk of Smell and Taste Disturbances in Type 2 Diabetes
The absolute risk appears low, but new data suggest small changes in smell and taste with GLP-1 treatment may exceed those already associate
mdsc.pe·15d agoGLP-1 receptor agonist use does not increase insulin discontinuation with type 2 diabetes
For veterans with type 2 diabetes (T2D) receiving basal insulin therapy, the addition of glucagon-like peptide-1 receptor agonists (GLP-1 RA
Can GLP-1 medications improve health in people with Type 2 diabetes and PAD?
Research Highlights: GLP-1RA (glucagon-like peptide-1 receptor agonist) medications, which are prescribed to treat Type 2 diabetes and to he
Study Probes Absolute Risk for ION With GLP-1 Agents
In patients with type 2 diabetes, GLP-1 RAs may be associated with a higher incidence of ischemic optic neuropathy than other medications, c
Comments
Sign in to join the conversation.
No comments yet. Be the first.